Ending the evidence gap for pregnancy, HIV and co‐infections: ethics guidance from the PHASES project
Authors: Lyerly Anne Drapkin , Beigi Richard , Bekker Linda‐Gail , Chi Benjamin H. , Cohn Susan E. , Diallo Dázon Dixon , Eron Joseph , Faden Ruth , Jaffe Elana , Kashuba Angela , Kasule Mary , Krubiner Carleigh , Little Maggie , Mfustso‐Bengo Joseph , Mofenson Lynne , Mwapasa Victor , Mworeko Lillian , Myer Landon , Penazzato Martina , Rid Annette , Shapiro Roger , Singh Jerome Amir , Sullivan Kristen , Vicari Marissa , Wambui Jacque , White Amina , Wickremsinhe Marisha , Wolf Leslie 
Published: December 2021

Introduction

While pregnant people have been an important focus for HIV research, critical evidence gaps remain regarding prevention, co‐infection, and safety and efficacy of new antiretroviral therapies in pregnancy. Such gaps can result in harm: without safety data, drugs used may carry unacceptable risks to the foetus or pregnant person; without pregnancy‐specific dosing data, pregnant people face risks of both toxicity and undertreatment; and delays in gathering evidence can limit access to beneficial next‐generation drugs. Despite recognition of the need, numerous barriers and ethical complexities have limited progress. We describe the process, ethical foundations, recommendations and applications of guidance for advancing responsible inclusion of pregnant people in HIV/co‐infections research.

Discussion

The 26‐member international and interdisciplinary Pregnancy and HIV/AIDS: Seeking Equitable Study (PHASES) Working Group was convened to develop ethics‐centred guidance for advancing timely, responsible HIV/co‐infections research with pregnant people. Deliberations over 3 years drew on extensive qualitative research, stakeholder engagement, expert consultation and a series of workshops. The guidance, initially issued in July 2020, highlights conceptual shifts needed in framing research with pregnant people, and articulates three ethical foundations to ground recommendations: equitable protection from drug‐related risks, timely access to biomedical advances and equitable respect for pregnant people's health interests. The guidance advances 12 specific recommendations, actionable within the current regulatory environment, addressing multiple stakeholders across drug development and post‐approval research, and organized around four themes: building capacity, supporting inclusion, achieving priority research and ensuring respect. The recommendations describe strategies towards ethically redressing the evidence gap for pregnant people around HIV and co‐infections. The guidance has informed key efforts of leading organizations working to advance needed research, and identifies further opportunities for impact by a range of stakeholder groups.

Conclusions

There are clear pathways towards ethical inclusion of pregnant people in the biomedical research agenda, and strong agreement across the HIV research community about the need for – and the promise of – advancing them. Those who fund, conduct, oversee and advocate for research can use the PHASES guidance to facilitate more, better and earlier evidence to optimize the health and wellbeing of pregnant people and their children.